MI-773
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206069

CAS#: 1303607-07-9

Description: MI-773 is a new small molecule inhibitor of the MDM2-p53 interaction, binds to MDM2 with high affinity (Ki=0.88 nM) and blocks the p53-MDM2 interaction. MI-773 is an isomer of MI-77301 (SAR405838).


Chemical Structure

img
MI-773
CAS# 1303607-07-9

Theoretical Analysis

MedKoo Cat#: 206069
Name: MI-773
CAS#: 1303607-07-9
Chemical Formula: C29H34Cl2FN3O3
Exact Mass: 561.20
Molecular Weight: 562.507
Elemental Analysis: C, 61.92; H, 6.09; Cl, 12.60; F, 3.38; N, 7.47; O, 8.53

Price and Availability

Size Price Availability Quantity
5mg USD 350 2 weeks
10mg USD 650 2 weeks
Bulk inquiry

Related CAS #: 1303607-07-9   1303607-60-4    

Synonym: MI773; MI-773; MI 773

IUPAC/Chemical Name: (2'R,3S,4'S,5'R)-6-Chloro-4'-(3-chloro-2-fluorophenyl)-2'-(2,2-dimethylpropyl)-1,2-dihydro-N-(trans-4-hydroxycyclohexyl)-2-oxospiro[3H-indole-3,3'-pyrrolidine]-5'-carboxamide

InChi Key: IDKAKZRYYDCJDU-HEVVSWJASA-N

InChi Code: InChI=1S/C29H34Cl2FN3O3/c1-28(2,3)14-22-29(19-12-7-15(30)13-21(19)34-27(29)38)23(18-5-4-6-20(31)24(18)32)25(35-22)26(37)33-16-8-10-17(36)11-9-16/h4-7,12-13,16-17,22-23,25,35-36H,8-11,14H2,1-3H3,(H,33,37)(H,34,38)/t16-,17-,22-,23+,25-,29+/m1/s1

SMILES Code: O=C([C@H](N[C@@H]1CC(C)(C)C)[C@H](C2=CC=CC(Cl)=C2F)[C@]31C(NC4=C3C=CC(Cl)=C4)=O)N[C@H]5CC[C@H](O)CC5

Appearance: Solid powder

Purity: >98%

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >5 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:         

Product Data:
Biological target: MI-773 is a potent MDM2-p53 protein‐protein interaction (PPI) inhibitor with high binding affinity against MDM2 (Kd=8.2 nM).
In vitro activity: The molecular mechanisms by which MI-773 exerted its effects were investigated using a microarray. The results showed that disturbance of the MDM2/p53 axis by MI-773 resulted in potent suppression of proliferation, induction of apoptosis and cell cycle arrest in NB cells. In addition, microarray analysis showed that MI-773 led to significant downregulation of genes involved in the G2/M phase checkpoint and upregulation of hallmark gene associated with the p53 pathway. Reference: Oncol Lett. 2021 Dec;22(6):838. https://pubmed.ncbi.nlm.nih.gov/34712362/
In vivo activity: To evaluate the anti-tumor effect of MI-773, this study administered it to mice harboring three different patient-derived xenograft (PDX) models of ACC expressing functional p53. Single-agent MI-773 caused tumor regression in the 3 PDX models of ACC studied here. The number of p53-positive cells was increased in MI-773-treated PDX tumors (P < 0.001), with a correspondent shift in p53 localization from the nucleus to the cytoplasm. Reference: Clin Cancer Res. 2016 Jul 15;22(14):3550-9. https://pubmed.ncbi.nlm.nih.gov/26936915/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 53.0 94.22

Preparing Stock Solutions

The following data is based on the product molecular weight 562.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Vuaroqueaux V, Hendriks HR, Al-Hasani H, Peille AL, Das S, Fiebig HH. Pharmacogenomics characterization of the MDM2 inhibitor MI-773 reveals candidate tumours and predictive biomarkers. NPJ Precis Oncol. 2021 Oct 28;5(1):96. doi: 10.1038/s41698-021-00235-7. PMID: 34711913; PMCID: PMC8553758. 2. Chen YL, Zhang ZM, Li XL, Tao YF, Wu SY, Fang F, Xie Y, Liao XM, Li G, Wu D, Wang HR, Zuo R, Cao HB, Pan JJ, Yu JJ, Zhang Z, Chu XR, Zhang YP, Feng CX, Wang JW, Lu J, Hu SY, Li ZH, Pan J. MI-773, a breaker of the MDM2/p53 axis, exhibits anticancer effects in neuroblastoma via downregulation of INSM1. Oncol Lett. 2021 Dec;22(6):838. doi: 10.3892/ol.2021.13099. Epub 2021 Oct 18. PMID: 34712362; PMCID: PMC8548782. 3. Andrews A, Warner K, Rodriguez-Ramirez C, Pearson AT, Nör F, Zhang Z, Kerk S, Kulkarni A, Helman JI, Brenner JC, Wicha MS, Wang S, Nör JE. Ablation of Cancer Stem Cells by Therapeutic Inhibition of the MDM2-p53 Interaction in Mucoepidermoid Carcinoma. Clin Cancer Res. 2019 Mar 1;25(5):1588-1600. doi: 10.1158/1078-0432.CCR-17-2730. Epub 2018 Nov 29. PMID: 30498096; PMCID: PMC6397688. 4. Warner KA, Nör F, Acasigua GA, Martins MD, Zhang Z, McLean SA, Spector ME, Chepeha DB, Helman J, Wick MJ, Moskaluk CA, Castilho RM, Pearson AT, Wang S, Nör JE. Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma. Clin Cancer Res. 2016 Jul 15;22(14):3550-9. doi: 10.1158/1078-0432.CCR-15-1698. Epub 2016 Mar 2. PMID: 26936915; PMCID: PMC4947417.
In vitro protocol: 1. Vuaroqueaux V, Hendriks HR, Al-Hasani H, Peille AL, Das S, Fiebig HH. Pharmacogenomics characterization of the MDM2 inhibitor MI-773 reveals candidate tumours and predictive biomarkers. NPJ Precis Oncol. 2021 Oct 28;5(1):96. doi: 10.1038/s41698-021-00235-7. PMID: 34711913; PMCID: PMC8553758. 2. Chen YL, Zhang ZM, Li XL, Tao YF, Wu SY, Fang F, Xie Y, Liao XM, Li G, Wu D, Wang HR, Zuo R, Cao HB, Pan JJ, Yu JJ, Zhang Z, Chu XR, Zhang YP, Feng CX, Wang JW, Lu J, Hu SY, Li ZH, Pan J. MI-773, a breaker of the MDM2/p53 axis, exhibits anticancer effects in neuroblastoma via downregulation of INSM1. Oncol Lett. 2021 Dec;22(6):838. doi: 10.3892/ol.2021.13099. Epub 2021 Oct 18. PMID: 34712362; PMCID: PMC8548782.
In vivo protocol: 1. Andrews A, Warner K, Rodriguez-Ramirez C, Pearson AT, Nör F, Zhang Z, Kerk S, Kulkarni A, Helman JI, Brenner JC, Wicha MS, Wang S, Nör JE. Ablation of Cancer Stem Cells by Therapeutic Inhibition of the MDM2-p53 Interaction in Mucoepidermoid Carcinoma. Clin Cancer Res. 2019 Mar 1;25(5):1588-1600. doi: 10.1158/1078-0432.CCR-17-2730. Epub 2018 Nov 29. PMID: 30498096; PMCID: PMC6397688. 2. Warner KA, Nör F, Acasigua GA, Martins MD, Zhang Z, McLean SA, Spector ME, Chepeha DB, Helman J, Wick MJ, Moskaluk CA, Castilho RM, Pearson AT, Wang S, Nör JE. Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma. Clin Cancer Res. 2016 Jul 15;22(14):3550-9. doi: 10.1158/1078-0432.CCR-15-1698. Epub 2016 Mar 2. PMID: 26936915; PMCID: PMC4947417.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Andrews A, Warner K, Rodriguez-Ramirez C, Pearson AT, Nör F, Zhang Z, Kerk S,
Kulkarni A, Helman JI, Brenner JC, Wicha MS, Wang S, Nör JE. Ablation of Cancer
Stem Cells by Therapeutic Inhibition of the MDM2-p53 Interaction in
Mucoepidermoid Carcinoma. Clin Cancer Res. 2019 Mar 1;25(5):1588-1600. doi:
10.1158/1078-0432.CCR-17-2730. Epub 2018 Nov 29. PubMed PMID: 30498096; PubMed
Central PMCID: PMC6397688.


2: Wong JH, Alfatah M, Sin MF, Sim HM, Verma CS, Lane DP, Arumugam P. A yeast
two-hybrid system for the screening and characterization of small-molecule
inhibitors of protein-protein interactions identifies a novel putative
Mdm2-binding site in p53. BMC Biol. 2017 Nov 9;15(1):108. doi:
10.1186/s12915-017-0446-7. PubMed PMID: 29121928; PubMed Central PMCID:
PMC5680816.


3: Lu J, Guan S, Zhao Y, Yu Y, Wang Y, Shi Y, Mao X, Yang KL, Sun W, Xu X, Yi JS,
Yang T, Yang J, Nuchtern JG. Novel MDM2 inhibitor SAR405838 (MI-773) induces
p53-mediated apoptosis in neuroblastoma. Oncotarget. 2016 Dec
13;7(50):82757-82769. doi: 10.18632/oncotarget.12634. PubMed PMID: 27764791;
PubMed Central PMCID: PMC5347730.


4: Nör F, Warner KA, Zhang Z, Acasigua GA, Pearson AT, Kerk SA, Helman JI,
Sant'Ana Filho M, Wang S, Nör JE. Therapeutic Inhibition of the MDM2-p53
Interaction Prevents Recurrence of Adenoid Cystic Carcinomas. Clin Cancer Res.
2017 Feb 15;23(4):1036-1048. doi: 10.1158/1078-0432.CCR-16-1235. Epub 2016 Aug
22. PubMed PMID: 27550999; PubMed Central PMCID: PMC5315632.


5: Warner KA, Nör F, Acasigua GA, Martins MD, Zhang Z, McLean SA, Spector ME,
Chepeha DB, Helman J, Wick MJ, Moskaluk CA, Castilho RM, Pearson AT, Wang S, Nör
JE. Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma. Clin Cancer Res.
2016 Jul 15;22(14):3550-9. doi: 10.1158/1078-0432.CCR-15-1698. Epub 2016 Mar 2.
PubMed PMID: 26936915; PubMed Central PMCID: PMC4947417.